Cargando…

P540: RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

Detalles Bibliográficos
Autores principales:	Amaya, Maria, Mcmahon, Christine, Aaron Gutman, Jonathan, Schwartz, Marc, Sevens, Brett, Sohalski, Connor, Tobin, Jennifer, Smith, Clayton, T Jordan, Craig, Aaron Pollyea, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428847/ http://dx.doi.org/10.1097/01.HS9.0000969068.95778.ba

Ejemplares similares

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
por: Gutman, Jonathan A., et al.
Publicado: (2023)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
por: Liu, Yifan, et al.
Publicado: (2023)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?
por: Stevens, Brett, et al.
Publicado: (2023)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
por: Cortes, Jorge, et al.
Publicado: (2023)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies
por: Savona, Michael R., et al.
Publicado: (2018)

Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
por: Masetti, Riccardo, et al.
Publicado: (2023)

Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine
por: Zhang, Alexander, et al.
Publicado: (2022)

Augmenting Venetoclax Activity Through Signal Transduction in AML
por: Bouligny, Ian Michael, et al.
Publicado: (2023)

P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Burkart, Madelyn, et al.
Publicado: (2023)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
por: Chen, Xiaotong, et al.
Publicado: (2023)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
por: Tong, Juan, et al.
Publicado: (2021)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
por: Babiker, Hani M., et al.
Publicado: (2020)

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
por: de Lima, Marcos, et al.
Publicado: (2018)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
por: Chesnokov, Mikhail S, et al.
Publicado: (2021)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
por: Zhigarev, Dmitry, et al.
Publicado: (2022)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
por: Zeidan, Amer M., et al.
Publicado: (2022)

Infectious complications following Venetoclax-Proteasome Inhibitor based regimens in relapsed myeloma: a single center retrospective analysis
por: Bernabei, Luca, et al.
Publicado: (2019)

Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
por: Xu, Linchun, et al.
Publicado: (2023)

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h2ttp5cf2dqrk2pj0bjvr8vim7